Agents that act luminally to treat diarrhoea and constipation

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 11, 2012, Pages 661-674

  Menees, Stacy ^a   Saad, Richard ^a   Chey, William D ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETORPHAN; ANTIDIARRHEAL AGENT; BERBERINE; BISACODYL; BISMUTH SALICYLATE; CANNABIS; CODEINE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CROFELEMER; DIOSMECTITE; DIPHENOXYLATE; DOCUSATE CALCIUM; DOCUSATE SODIUM; LACTULOSE; LAXATIVE; LINACLOTIDE; LOPERAMIDE; LUBIPROSTONE; MACROGOL 3350; MAGNESIUM SALT; MISOPROSTOL; OPIATE; PICOSULFATE SODIUM; PLACEBO; PLECANATIDE; PROBIOTIC AGENT; RIFAXIMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMAL FECES; ACUTE DIARRHEA; BLOATING; CHRONIC DIARRHEA; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON MOTILITY; CONSTIPATION; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ESCHERICHIA COLI INFECTION; EUPHORIA; EVENING DOSAGE; FATIGUE; FLATULENCE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH FIBER DIET; HUMAN; INFECTIOUS DIARRHEA; INTESTINAL SECRETION; INTESTINE ABSORPTION; IRRITABLE COLON; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; TASTE DISORDER; TONGUE DISEASE; TRAVELLER DIARRHEA; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ANTI-BACTERIAL AGENTS; ANTIDIARRHEALS; CATHARTICS; CONSTIPATION; DIARRHEA; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINAL ABSORPTION; PROBIOTICS;

EID: 84868568067     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.162     Document Type: Review

References (173)

1. Shaheen, N. J. et al. The burden of gastrointestinal and liver diseases, 2006. Am. J. Gastroenterol. 101, 2128-2138 (2006).
2. Everhart, J. E. & Ruhl, C. E. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 136, 741-754 (2009).
3. Propulsid® (cisapride) package information (Janssen Pharmaceutica, Titusville, NJ, USA, 1995).
4. FDA Zelnorm (tegaserod maleate) information [online], http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051284. htm.\
5. Lewis, J. H. Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective. Expert Rev. Gastroenterol. Hepatol. 4, 13-29 (2010).
6. Kirwan, W. O. et al. Bile acids and colonic motility in the rabbit and the human. Gut 16, 894-902 (1975).
7. Doherty, N. S. & Hancock, A. A. Role of alpha 2 adrenergic receptors in the control of diarrhea and intestinal motility. J. Pharmacol. Exp. Ther. 225, 269-274 (1983). (Pubitemid 13091212)
8. Chey, W. D., Maneerattaporn, M. & Saad, R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 5, 253-266 (2011).
9. Ford, A. C. et al. Efficacy of 5 HT3 antagonists and 5 HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am. J. Gastroenterol. 104, 1831-1843 (2009).
10. Camilleri, M. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clin. Pharmacol. Ther. 91, 44-59 (2012).
11. Feldman, M., Friedman, L. S. & Brandt, L. J. (eds) Sleisenger and Fordtran's Gastrointestinal and Liver Disease 9th edn. Vol.1. Saunders, Elsevier Philadelphia (2010).
12. Fine, K. D. & Schiller, L. R. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 116, 1464-1486 (1999). (Pubitemid 29258896)
13. Pathan, H. & Williams, J. Basic opioid pharmacology: an update. Br. J. Pain 6, 11-16 (2012).
14. Sternini, C., Patierno, S., Selmer, I. S. & Kirchgessner, A. The opioid system in the gastrointestinal tract. Neurogastroenterol. Motil. 16 (Suppl. 2), 3-16 (2004). (Pubitemid 39468862)
15. Holzer, P., Schicho, R., Holzer-Petsche, U. & Lippe, I. T. The gut as a neurological organ. Wien Klin. Wochenschr. 113, 647-660 (2001). (Pubitemid 32899957)
16. Wood, J. D. & Galligan, J. J. Function of opioids in the enteric nervous system. Neurogastroenterol. Motil. 16 (Suppl. 2), 17-28 (2004). (Pubitemid 39468863)
17. Kurz, A. & Sessler, D. I. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63, 649-671 (2003). (Pubitemid 36408072)
18. Turnberg, L. A. Antisecretory activity of opiates in vitro and in vivo in man. Scand. J. Gastroenterol. Suppl. 84, 79-83 (1983). (Pubitemid 13061952)
19. De Schepper, H. U., Cremonini, F., Park, M. I. & Camilleri, M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol. Motil. 16, 383-394 (2004). (Pubitemid 39140632)
20. Imodium® oral capsules package information (McNeil Consumer Healthcare, Fort Washington, PA, USA, 2005).
21. De Luca, A. & Coupar, I. M. Insights into opioid action in the intestinal tract. Pharmacol. Ther. 69, 103-115 (1996). (Pubitemid 26111425)
22. Heel, R. C., Brogden, R. N., Speight, T. M. & Avery, G. S. Loperamide: A review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs 15, 33-52 (1978). (Pubitemid 8260089)
23. van Loon, F. P., Bennish, M. L., Speelman, P. & Butler, C. Double blind trial of loperamide for treating acute watery diarrhoea in expatriates in Bangladesh. Gut 30, 492-495 (1989).
24. Cann, P. A., Read, N. W., Holdsworth, C. D. & Barends, D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig. Dis. Sci. 29, 239-247 (1984). (Pubitemid 14158881)
25. Efskind, P. S., Bernklev, T. & Vatn, M. H. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand. J. Gastroenterol. 31, 463-468 (1996). (Pubitemid 26153637)
26. Tytgat, G. N. & Huibregtse, K. Loperamide and ileostomy output- placebo controled double-blind crossover study. Br. Med. J. 2, 667 (1975).
27. King, R. F. G. J., Norton, T. & Hill, G. L. A double-blind crossover study of the effect of loperamide hydrochloride and codeine phosphase on ileostomy output. Aust. N. Z. J. Surg. 52, 121-124 (1982). (Pubitemid 12124660)
28. Weiner, C P. Drugs for Pregnant and Lactating Women, 2nd edn (Saunders Inc., Philadelphia, 2009).
29. Lehert, P. et al. Racecadotril for childhood gastroenteritis: an individual patient data meta-analysis. Dig. Liver Dis. 43, 707-713 (2011).
30. Hamza, H., Ben Khalifa, H., Baumer, P., Berard, H. & Lecomte, J. M. Racecadotril versus placebo in the treatment of acute diarrhoea in adults. Aliment Pharmacol. Ther. 13 (Suppl. 6), 15-19 (1999). (Pubitemid 30019156)
31. Roge, J., Baumer, P., Berard, H., Schwartz, J. C. & Lecomte, J. M. The enkephalinase inhibitor, acetorphan, in acute diarrhoea. A double-blind, controlled clinical trial versus loperamide. Scand. J. Gastroenterol. 28, 352-354 (1993).
32. Vetel, J. M., Berard, H., Fretault, N. & Lecomte, J. M. Comparison of racecadotril and loperamide in adults with acute diarrhoea. Aliment Pharmacol. Ther. 13 (Suppl. 6), 21-26 (1999). (Pubitemid 30019157)
33. Lecomte, J. M. An overview of clinical studies with racecadotril in adults. Int. J. Antimicrob. Agents 14, 81-87 (2000). (Pubitemid 30136407)
34. Wang, H. H. A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults. World J. Gastroenterol. 11, 1540-1543 (2005).
35. Pattni, S. & Walters, J. R. Recent advances in the understanding of bile acid malabsorption. Br. Med. Bull. 92, 79-93 (2009).
36. Mekjian, H. S., Phillips, S. F. & Hofmann, A. F. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J. Clin. Invest. 50, 1569-1577 (1971).
37. McJunkin, B., Fromm, H., Sarva, R. P. & Amin, P. Factors in the mechanism of diarrhea in bile acid malabsorption: fecal pH - a key determinant. Gastroenterology 80, 1454-1464 (1981). (Pubitemid 11113561)
38. Williams, A. J., Merrick, M. V. & Eastwood, M. A. Idiopathic bile acid malabsorption- a review of clinical presentation, diagnosis, and response to treatment. Gut 32, 1004-1006 (1991).
39. Smith, M. J. et al. Bile acid malabsorption in persistent diarrhoea. J. R. Coll. Physicians Lond. 34, 448-451 (2000).
40. Sinha, L., Liston, R., Testa, H. J. & Moriarty, K. J. Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment. Pharmacol. Ther. 12, 839-844 (1998). (Pubitemid 28428947)
41. Wedlake, L. et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 30, 707-717 (2009).
42. Hiatt, J. G., Shamsie, S. G. & Schectman, G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am. J. Manag. Care 5, 437-444 (1999). (Pubitemid 29202923)
43. Wedlake, L., Thomas, K., Lalji, A., Anagnostopoulos, C. & Andreyev, H. J. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: A retrospective chart review and patient questionnaire. Clin. Ther. 31, 2549-2558 (2009).
44. Odunsi-Shiyanbade, S. T. et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin. Gastroenterol. Hepatol. 8, 159-165 (2010).
45. Guerrant, R. L. et al. Practice guidelines for the management of infectious diarrhea. Clin. Infect. Dis. 32, 331-351 (2001). (Pubitemid 32173618)
46. Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6, 2383-2400 (2008).
47. Beaugerie, L. & Petit, J. C. Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best Pract. Res. Clin. Gastroenterol. 18, 337-352 (2004).
48. Wistrom, J. et al. Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. Ann. Intern. Med. 117, 202-208 (1992).
49. Neill, M. A. et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann. Intern. Med. 114, 195-199 (1991).
50. Wong, C. S., Jelacic, S., Habeeb, R. L., Watkins, S. L. & Tarr, P. I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342, 1930-1936 (2000). (Pubitemid 30419087)
51. Huang, D. B. & DuPont, H. L. Rifaximin - a novel antimicrobial for enteric infections. J. Infect. 50, 97-106 (2005).
52. Scarpignato, C. & Pelosini, I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 73 (Suppl. 1), 13-27 (2006).
53. Salix Pharmaceuticals Inc. Xifaxan® oral tablets prescribing information [online], http://www.salix.com/assets/pdf/prescribe-info/xifaxanpi. pdf (2010).
54. Menees, S. B., Maneerattannaporn, M., Kim, H. M. & Chey, W. D. The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis. Am. J. Gastroenterol. 107, 28-35 (2012).
55. Pimentel, M. et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med. 364, 22-32 (2011).
56. Chang, L. et al. Tu1403 Safety and tolerability profile of rifaximin for treatment of IBS without constipation: results of a pooled analysis of double-blind, placebo-controlled randomized controlled trials. Gastroenterology 142, S-823 (2012).
57. Brenner, D. M., Moeller, M. J., Chey, W. D. & Schoenfeld, P. S. The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am. J. Gastroenterol. 104, 1033-1049 (2009).
58. Allen, S. J., Martinez, E. G., Gregorio, G. V. & Dans L. F. Probiotics for treating acute infectious diarrhoea. Cochrane Database of Systematic Reviews, Issue 11 Art. No.: CD003048. http://dx.doi.org/10.1002/1002. 14651858.CD003048.pub3.
59. Brenner, D. M., Moeller, M. J., Chey, W. D. & Schoenfeld, P. S. The utility of probiotics in the treatment of irritable bowel syndrome: A systematic review. Am. J. Gastroenterol. 104, 1033-1049 (2009).
60. Ringel, Y. et al. 1318 Probiotic Bifidobacterium longum subsp. infantis 35624 in a non-patient population with a history of abdominal discomfort and bloating. Am. J. Gastroenterol. 106, S503 (2011).
61. Gorbach, S. L. Bismuth therapy in gastrointestinal diseases. Gastroenterology 99, 863-875 (1990). (Pubitemid 20243385)
62. Ericsson, C. D., Tannenbaum, C. & Charles, T. T. Antisecretory and antiinflammatory properties of bismuth subsalicylate. Rev. Infect. Dis. 12 (Suppl. 1), S16-S20 (1990). (Pubitemid 20060276)
63. Sox, T. E. & Olson, C. A. Binding and killing of bacteria by bismuth subsalicylate. Antimicrob. Agents Chemother. 33, 2075-2082 (1989). (Pubitemid 20000139)
64. Manhart, M. D. In vitro antimicrobial activity of bismuth subsalicylate and other bismuth salts. Rev. Infect. Dis. 12 (Suppl. 1), S11-S15 (1990). (Pubitemid 20060275)
65. Ericsson, C. D., Evans, D. G., DuPont, H. L., Evans, D. J. Jr & Pickering, L. K. Bismuth subsalicylate inhibits activity of crude toxins of Escherichia coli and Vibrio cholerae. J. Infect. Dis. 136, 693-696 (1977). (Pubitemid 8223683)
66. Finck, A. D. & Katz, R. L. Prevention of cholera-induced intestinal secretion in the cat by aspirin. Nature 238, 273-274 (1972).
67. Farris, R. K., Tapper, E. J., Powell, D. W. & Morris, S. M. Effect of aspirin on normal and cholera toxin-stimulated intestinal electrolyte transport. J. Clin. Invest. 57, 916-924 (1976).
68. DuPont, H. L. et al. Prevention of traveler's diarrhea (emporiatric enteritis). Prophylactic administration of subsalicylate bismuth). JAMA 243, 237-241 (1980). (Pubitemid 10201603)
69. Steffen, R. Epidemiologic studies of travelers' diarrhea, severe gastrointestinal infections, and cholera. Rev. Infect. Dis. 8 (Suppl. 2), S122-S130 (1986).
70. Pepto-Bismol® (bismuth subsalicylate) package insert. (Procter & Gamble Pharmaceuticals, Cincinnati, OH, 2006).
71. Soriano-Brucher, H. et al. Bismuth subsalicylate in the treatment of acute diarrhea in children: A clinical study. Pediatrics 87, 18-27 (1991).
72. Figueroa-Quintanilla, D. et al. A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease. N. Engl. J. Med. 328, 1653-1658 (1993). (Pubitemid 23157346)
73. Pardi, D. S., Ramnath, V. R., Loftus, E. V. Jr, Tremaine, W. J. & Sandborn, W. J. Lymphocytic colitis: clinical features, treatment, and outcomes. Am. J. Gastroenterol. 97, 2829-2833 (2002). (Pubitemid 35265435)
74. Fine, K. D. & Lee, E. L. Efficacy of open-label bismuth subsalicylate for the treatment of microscopic colitis. Gastroenterology 114, 29-36 (1998). (Pubitemid 28020951)
75. Amaro, R., Poniecka, A. & Rogers, A. I. Collagenous colitis treated successfully with bismuth subsalicylate. Dig. Dis. Sci. 45, 1447-1450 (2000). (Pubitemid 30636524)
76. Sack, R. B. & Froehlich, J. L. Berberine inhibits intestinal secretory response of Vibrio cholerae and Escherichia coli enterotoxins. Infect. Immun. 35, 471-475 (1982). (Pubitemid 12164739)
77. Kaneda, Y., Torii, M., Tanaka, T. & Aikawa, M. In vitro effects of berberine sulphate on the growth and structure of Entamoeba histolytica, Giardia lamblia and Trichomonas vaginalis. Ann. Trop. Med. Parasitol. 85, 417-425 (1991).
78. Amin, A. H., Subbaiah, T. V. & Abbasi, K. M. Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Can. J. Microbiol 15, 1067-1076 (1969).
79. Sun, D., Abraham, S. N. & Beachey, E. H. Influence of berberine sulfate on synthesis and expression of Pap. fimbrial adhesin in uropathogenic Escherichia coli. Antimicrob. Agents Chemother. 32, 1274-1277 (1988).
80. Rabbani, G. H., Butler, T., Knight, J., Sanyal, S. C. & Alam, K. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J. Infect. Dis. 155, 979-984 (1987). (Pubitemid 17062836)
81. Choudhry, V. P., Sabir, M. & Bhide, V. N. Berberine in giardiasis. Indian Pediatr. 9, 143-146 (1972).
82. Li, G. H. et al. Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy. Med. Oncol. 27, 919-925 (2010).
83. Tradtrantip, L., Namkung, W. & Verkman, A. S. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol. Pharmacol. 77, 69-78 (2010).
84. DiCesare, D. et al. A double blind, randomized, placebo-controlled study of SP 303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am. J. Gastroenterol. 97, 2585-2588 (2002).
85. Bardhan P. K. et al. Evaluation of safety and efficacy of a novel anti-secretory anti-diarrheal agent Crofelemer (NP-303), in combination with a single oral dose of azithromycin for the treatment of acute dehydrating diarrhea caused by Vibrio cholera [abstract]. Presented at US Japan CMSP 43rd Conference on Cholera and Other Bacterial Enteric Infections http://www.napopharma.com/ publications/NIAID-Japan-Cholera-Short-Abstract-10.15.08.pdf (2008).
86. Mangel, A. W. & Chaturvedi, P. Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 78, 180-186 (2008).
87. Holodniy, M. et al. A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP 303 for the symptomatic treatment of diarrhea in patients with AIDS. Am. J. Gastroenterol. 94, 3267-3273 (1999).
88. Salix Pharmaceuticals. Crofelemer ADVENT Trial Demonstrates Highly Statistically Significant Results in the Treatment of HIV-Associated Diarrhea [online], http://www.salix.com/news-media/news/previous-years-news/crofelemer- advent-trial-demonstrates-highly-statistically-significant-results-in-the- treatment-of-hiv-associated-diarrhea.aspx (2010).
89. AIDS Community Research Initiative of America. FDA Grants Priority Review for Crofelemer [online], http://www.acria.org/content/fda-grants-priority- review-crofelmer (2012).
90. Dupont, C. et al. Effect of diosmectite on intestinal permeability changes in acute diarrhea: A double-blind placebo-controlled trial. J. Pediatr. Gastroenterol. Nutr. 14, 413-419 (1992).
91. Mahraoui, L., Heyman, M., Plique, O., Droy Lefaix, M. T. & Desjeux, J. F. Apical effect of diosmectite on damage to the intestinal barrier induced by basal tumour necrosis factor-α. Gut 40, 339-343 (1997). (Pubitemid 27145646)
92. Fioramonti, J., Fargeas, M. J. & Bueno, L. Action of T 2 toxin on gastrointestinal transit in mice: protective effect of an argillaceous compound. Toxicol. Lett. 36, 227-232 (1987). (Pubitemid 17111205)
93. More, J., Benazet, F., Fioramonti, J. & Droy-Lefaix, M. T. Effects of treatment with smectite on gastric and intestinal glycoproteins in the rat: A histochemical study. Histochem. J. 19, 665-670 (1987).
94. Gonzalez, R. et al. Anti-inflammatory effect of diosmectite in hapten-induced colitis in the rat. Br. J. Pharmacol. 141, 951-960 (2004). (Pubitemid 38510078)
95. Leber, W. A new suspension form of smectite (Liquid 'Diasorb') for the treatment of acute diarrhoea: A randomized comparative study. Pharmatherapeutica 5, 256-260 (1988).
96. Yen, Z. S. & Lai, M. S. Best evidence topic report. Smectite for acute diarrhoea in children. Emerg. Med. J. 23, 65-66 (2006).
97. Guarino, A. et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J. Pediatr. Gastroenterol. Nutr. 46 (Suppl. 2), S81-S122 (2008). (Pubitemid 351644171)
98. Chang, F. Y., Lu, C. L., Chen, C. Y. & Luo, J. C. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome. J. Gastroenterol. Hepatol. 22, 2266-2272 (2007).
99. Dumitrascu, D. L., Stanculete, M., Mitrea, I., Dumitrascu, D. M. & Farcas, A. The effect of two antidiarrhoeal drugs on the psychosocial adjustment to illness in chronic functional diarrhoea. Rom. J. Intern. Med. 42, 191-197 (2004).
100. Drossman, D. et al. (eds.) Rome III: The Functional Gastrointestinal Disorders, Third Edition (Degnon Associates, Inc., McLean, VA, 2006).
101. Stevens, J., Van Soest, P. J., Robertson, J. B. & Levitsky, D. A. Comparison of the effects of psyllium and wheat bran on gastrointestinal transit time and stool characteristics. J. Am. Diet. Assoc. 88, 323-326 (1988). (Pubitemid 18085100)
102. Graham, D. Y., Moser, S. E. & Estes, M. K. The effect of bran on bowel function in constipation. Am. J. Gastroenterol. 77, 599-603 (1982). (Pubitemid 12061411)
103. Trowell, H. Definition of dietary fiber and hypotheses that it is a protective factor in certain diseases. Am. J. Clin. Nutr. 29, 417-427 (1976).
104. Lindberg, G. et al. World Gastroenterology Organisation global guideline: constipation - a global perspective. J. Clin. Gastroenterol. 45, 483-487 (2011).
105. Locke, G. R. 3rd, Pemberton, J. H. & Phillips, S. F. American Gastroenterological Association Medical Position Statement: guidelines on constipation. Gastroenterology 119, 1761-1766 (2000). (Pubitemid 32198702)
106. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am. J. Gastroenterol. 100 (Suppl. 1), S1-S4 (2005).
107. Suares, N. C. & Ford, A. C. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment. Pharmacol. Ther. 33, 895-901 (2011).
108. Badiali, D. et al. Effect of wheat bran in treatment of chronic nonorganic constipation. A double-blind controlled trial. Dig. Dis. Sci. 40, 349-356 (1995).
109. Anderson, A. S. & Whichelow, M. J. Constipation during pregnancy: dietary fibre intake and the effect of fibre supplementation. Hum. Nutr. Appl. Nutr. 39, 202-207 (1985).
110. Singh, S. & Rao, S. S. Pharmacologic management of chronic constipation. Gastroenterol. Clin. North Am. 39, 509-527 (2010).
111. Chapman, R. W., Sillery, J., Fontana, D. D., Matthys, C. & Saunders, D. R. Effect of oral dioctyl sodium sulfosuccinate on intake-output studies of human small and large intestine. Gastroenterology 89, 489-493 (1985). (Pubitemid 15239149)
112. Brandt, L. J. et al. Systematic review on the management of chronic constipation in North America. Am. J. Gastroenterol. 100 (Suppl. 1), S5-S21 (2005).
113. Ramkumar, D. & Rao, S. S. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am. J. Gastroenterol. 100, 936-971 (2005). (Pubitemid 40592390)
114. Berger, M. B., Damico, N. J., Menees, S. B., Fenner, D. E. & Haefner, H. K. Rates of self-reported urinary, gastrointestinal, and pain comorbidities in women with vulvar lichen sclerosus. J. Low. Genit. Tract Dis. 16, 285-289 (2012).
115. Andorsky, R. I. & Goldner, F. Colonic lavage solution (polyethylene glycol electrolyte lavage solution) as a treatment for chronic constipation: A double-blind, placebo-controlled study. Am. J. Gastroenterol. 85, 261-265 (1990). (Pubitemid 20090040)
116. Corazziari, E. et al. Small volume isosmotic polyethylene glycol electrolyte balanced solution (PMF 100) in treatment of chronic nonorganic constipation. Dig. Dis. Sci. 41, 1636-1642 (1996). (Pubitemid 26285752)
117. Corazziari, E. et al. Long term efficacy, safety, and tolerabilitity of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF 100) in the treatment of functional chronic constipation. Gut 46, 522-526 (2000). (Pubitemid 30305817)
118. DiPalma, J. A., DeRidder, P. H., Orlando, R. C., Kolts, B. E. & Cleveland, M. B. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am. J. Gastroenterol. 95, 446-450 (2000). (Pubitemid 30106174)
119. Cleveland, M. V., Flavin, D. P., Ruben, R. A., Epstein, R. M. & Clark, G. E. New polyethylene glycol laxative for treatment of constipation in adults: A randomized, double-blind, placebo-controlled study. South. Med. J. 94, 478-481 (2001). (Pubitemid 33643475)
120. DiPalma, J. A., Cleveland, M. B., McGowan, J. & Herrera, J. L. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South. Med. J. 100, 1085-1090 (2007). (Pubitemid 350071173)
121. Dipalma, J. A., Cleveland, M. V., McGowan, J. & Herrera, J. L. A randomized, multicenter, placebo- controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am. J. Gastroenterol. 102, 1436-1441 (2007). (Pubitemid 46976282)
122. Attar, A. et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 44, 226-230 (1999). (Pubitemid 29119366)
123. Di Palma, J. A., Cleveland, M. V., McGowan, J. & Herrera, J. L. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. Am. J. Gastroenterol. 102, 1964-1971 (2007). (Pubitemid 47301532)
124. MiraLAX®, polyethylene glycol 3350 oral powder package information Merck & Co., Inc., NJ, USA 2001.
125. Szojda, M. M. Differences in taste between two polyethylene glycol preparations. J. Gastrointest. Liver Dis. 16, 379-381 (2007).
126. Sanders, J. F. Lactulose syrup assessed in a double-blind study of elderly constipated patients. J. Am. Geriatr Soc. 26, 236-239 (1978). (Pubitemid 8344254)
127. Bass, P. & Dennis, S. The laxative effects of lactulose in normal and constipated subjects. J. Clin. Gastroenterol. 3 (Suppl. 1), 23-28 (1981). (Pubitemid 12181853)
128. Lactulose oral solution, package information. (Roxane Laboratories, Inc., Columbus, OH, 2007).
129. Clausen, M. R. & Mortensen, P. B. Lactulose, disaccharides and colonic flora. Clinical Consequences Drugs 53, 930-942 (1997).
130. Kinnunen, O. Constipation in elderly long-stay patients: its treatment by magnesium hydroxide and bulk-laxative. Ann. Clin. Res. 19, 321-323 (1987). (Pubitemid 18051852)
131. Frexinos, J. Effects of sennosides on colonic myoelectrical activity in man. Dig. Dis. Sci. 34, 214-219 (1989). (Pubitemid 19068170)
132. Materia, E., Corraziari, E., Bausano, G., Anzini, F. & Torsoli, A. Effect of bisacodyl on motor activity of sigmoid colon. Ital. J. Gastroenterol. 20, 246-249 (1988). (Pubitemid 19052798)
133. Schang, J. C. Changes in colonic myoelectric spiking activity during stimulation by bisacodyl. Can. J. Physiol. Pharmacol. 64, 39-43 (1986). (Pubitemid 16109707)
134. Ikarashi, N. The laxative effect of bisacodyl is attributable to decreased aquaporin 3 expression in the colon induced by increased PGE2 secretion from macrophages. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G887-G895 (2011).
135. Kamm, M. A. et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin. Gastroenterol. Hepatol. 9, 577-583 (2011).
136. Mueller-Lissner, S. et al. Multicenter, 4 week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am. J. Gastroenterol. 105, 897-903 (2010).
137. Dulcolax® bisacodyl package information (Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, 1994).
138. Fleet Flavored Castor Oil®, package information (Fleet, Lynchbury, VA, 1991).
139. Gentle Nature®, sennosides package information (Sandoz Pharmaceuticals, East Hanover, NY, USA, 1991).
140. Muller-Lissner, S. A., Kamm, M. A., Scarpignato, C. & Wald, A. Myths and misconceptions about chronic constipation. Am. J. Gastroenterol. 100, 232-242 (2005). (Pubitemid 41623292)
141. Freeman, H. J. Melanosis in the small and large intestine. World J. Gastroenterol. 14, 4296-4299 (2008).
142. Wald, A. Is chronic use of stimulant laxatives harmful to the colon? J. Clin. Gastroenterol. 36, 386-389 (2003). (Pubitemid 36459131)
143. Soffer, E. E., Metcalf, A. & Launspach, J. Misoprostol is effective treatment for patients with severe chronic constipation. Dig. Dis. Sci. 39, 929-933 (1994). (Pubitemid 24188831)
144. Mifeprex® Oral Tablet, mifepristone oral tablet package information (Danco Laboratories, LLC, New York, NY, 2005).
145. Jentsch, T. J., Stein, V., Weinreich, F. & Zdebik, A. A. Molecular structure and physiological function of chloride channels. Physiol. Rev. 82, 503-568 (2002). (Pubitemid 34654460)
146. Suzuki, M., Morita, T. & Iwamoto, T. Diversity of ClY channels. Cell. Mol. Life Sci. 63, 12-24 (2006).
147. Camilleri, M. et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G942-947 (2006).
148. Andresen, V. et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 133, 761-768 (2007). (Pubitemid 47374145)
149. Cuppoletti, J. et al. SPI 0211 activates T84 cell chloride transport and recombinant human ClC 2 chloride currents. Am. J. Physiol. Cell Physiol. 287, C1173-C1183 (2004). (Pubitemid 39382875)
150. Fukudo, S., Hongo, M., Kaneko, H. & Ueno, R. Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: A randomized, placebo-controlled and dose-finding study. Neurogastroenterol. Motil. 23, 544-e205 (2011).
151. Barish, C. F., Drossman, D., Johanson, J. F. & Ueno, R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig. Dis. Sci. 55, 1090-1097 (2010).
152. Drossman, D. A. et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment. Pharmacol. Ther. 29, 329-341 (2009).
153. Johanson, J. F., Drossman, D. A., Panas, R., Wahle, A. & Ueno, R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 27, 685-696 (2008). (Pubitemid 351406304)
154. Johanson, J. F., Morton, D., Geenen, J. & Ueno, R. Multicenter, 4 week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type 2 chloride channel activator, in patients with chronic constipation. Am. J. Gastroenterol. 103, 170-177 (2008).
155. Johanson, J. F. & Ueno, R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: A double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment. Pharmacol. Ther. 25, 1351-1361 (2007). (Pubitemid 46763456)
156. Amitiza®, lubiprostone oral capsules package information [online], http://www.amitiza.com (Sucampo Pharma America, Inc., Bethesda, MD, and Takeda Pharmaceuticals America, Inc., Deerfield, IL. USA, 2011).
157. Chey, W. D. et al. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 35, 587-599 (2012).
158. Saad, R. & Chey, W. D. Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation. Expert Rev. Gastroenterol. Hepatol. 2, 497-508 (2008).
159. Bryant, A. P. et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 86, 760-765 (2010).
160. Lembo, A. J. et al. Two randomized trials of linaclotide for chronic constipation. N. Engl. J. Med. 365, 527-536 (2011).
161. Lembo, A. J. et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138, 886-895 e1 (2010).
162. Johnston, J. M. et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 139, 1877-1886 e2 (2010).
163. Chey, W. et al. Efficacy and safety of once-daily linaclotide administered orally for 12 weeks to patients with IBS C: pooled results from two randomized, double-blind, placebo-controlled phase 3 trials. Am. J. Gastroenterol. 106, S504-S505 (2011).
164. Shailubhai, K. et al. Plecanatide, a guanylate cyclase C agonist, improves bowel habits and symptoms associated with chronic constipation in a phase IIa clinical study. Am. J. Gastroenterol. 106, S502 (2011).
165. Rao, A. S. et al. Chenodeoxycholate in females with irritable bowel syndrome-constipation: A pharmacodynamic and pharmacogenetic analysis. Gastroenterology 139, 1549-1558e1 (2010).
166. Maneerattanaporn, M. & Chey, W. D. Targeting bile acids in the treatment of constipation. Expert Rev. Gastroenterol. Hepatol. 5, 657-659 (2011).
167. Chey, W. D., Camilleri, M., Chang, L., Rikner, L. & Graffner, H. A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am. J. Gastroenterol. 106, 1803-1812 (2011).
168. Agrawal, A. et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN 173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 29, 104-114 (2009).
169. Riezzo, G. et al. Randomised clinical trial: efficacy of Lactobacillus paracasei-enriched artichokes in the treatment of patients with functional constipation - a double-blind, controlled, crossover study. Aliment. Pharmacol. Ther. 35, 441-450 (2012).
170. Chmielewska, A. & Szajewska, H. Systematic review of randomised controlled trials: probiotics for functional constipation. World J. Gastroenterol. 16, 69-75 (2010).
171. Attaluri, A., Donahoe, R., Valestin, J., Brown, K. & Rao, S. S. C. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Aliment. Pharmacol. Ther. 33, 822-828 (2011).
172. Cheng, C. W., Bian, Z. X., Zhu, L. X., Wu, J. C. Y. & Sung, J. J. Y. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am. J. Gastroenterol. 106, 120-129 (2011).
173. FDA pregnancy categories [online], http://depts.washington.edu/druginfo/ Formulary/Pregnancy.pdf (2004).